Markers for roscovitine
AssigneeCyclacel Limited
InventorsSimon Green, Paul Workman, Steven Whittaker
Life of this patent
Estimating the term…
Abstract
The present invention relates to pharmacodynamic markers for CDKIs including the candidate 2,6,9-tri-substituted purine known as roscovitine. The identity of these markers facilitates the convenient identification of roscovitine-like activity both in vitro and in vivo.
Claims20
A method of monitoring the activity of roscovitine comprising:
- (i) administering roscovitine to a cell, group of cells, an animal model or human;
- (ii) measuring gene expression in samples derived from the treated and the untreated cells, animal or human;
- and
- (iii) detecting an increase or a decrease in gene expression of at least one of the genes identified in FIGS. 1 through 8 in the treated sample as compared to the untreated sample as an indication of roscovitine activity.
A method according to claim, wherein the group of cells is a cell culture.
A method of assessing suitable dose levels of roscovitine comprising monitoring the degree and rate of expression of at least one of the genes identified in FIGS. 1 through 8 after administration of roscovitine to a cell, group of cells, animal model or human.
A method of identifying a candidate drug having roscovitine-like activity comprising administering said candidate drug to cell, group of cells, animal model or human, and monitoring the presence or absence of at least one of the genes as identified in FIGS. 1 through 8.
A method of monitoring the activity of roscovitine comprising:
- (i) administering roscovitine to a cell, group of cells, an animal model or human;
- (ii) measuring the expression of at least one gene derived from the treated and the untreated cells, animal or human, wherein said at least one gene is selected from the group consisting of the genes listed in FIGS. 1 through 8;
- and
- (iii) detecting an increase or a decrease in gene expression of at least one of the genes identified in FIGS. 1 through 8 in the treated sample.
A kit for assessing the activity of roscovitine comprising an antibody for each of at least one of the genes as identified in FIGS. 1 through 8.
A kit for assessing the activity of roscovitine comprising nucleic acid probes which specifically hybridizes to at least one of said genes identified in FIGS. 1 through 8.
A method of monitoring the activity of a CDKI comprising:
- (i) administering said CDKI to a cell, group of cells, an animal model or human;
- and
- (ii) measuring the expression of at least one of the genes identified in any of FIGS. 1 thorugh 8 in samples derived from the treated and the untreated cells, animal or human;
- and
- (iii) detecting an increase or a decrease in expression of at least one of the genes identified in any of FIGS. 1 through 8 in the treated sample as compared to the untreated sample as an indication of CDKI activity.
Dependencies are inferred from the claim text.